P
Patrick Mayeux
Researcher at University of Paris
Publications - 189
Citations - 11518
Patrick Mayeux is an academic researcher from University of Paris. The author has contributed to research in topics: Erythropoietin receptor & Phosphorylation. The author has an hindex of 59, co-authored 187 publications receiving 10582 citations. Previous affiliations of Patrick Mayeux include French Institute of Health and Medical Research & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
Nicole Casadevall,Joelle Nataf,Beatrice Viron,Amir Kolta,Jean-Jacques Kiladjian,Philippe Martin-Dupont,Patrick Michaud,Thomas Papo,Valérie Ugo,Irène Teyssandier,Bruno Varet,Patrick Mayeux +11 more
TL;DR: In this article, the authors identified 13 patients in whom pure red-cell aplasia developed during treatment with recombinant human erythropoietin (epoetin), and investigated whether there was an immunologic basis for the anemia in these patients.
Journal ArticleDOI
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Frédéric Pène,Yann-Erick Claessens,Odile Muller,Franck Viguié,Patrick Mayeux,François Dreyfus,Catherine Lacombe,Didier Bouscary +7 more
TL;DR: The results suggest that PI 3-K has a major role in the control of proliferation and apoptosis of growth factor-independent MM cell lines.
Journal ArticleDOI
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Nathalie Jacque,Anne Marie Ronchetti,Clément Larrue,Clément Larrue,Godelieve Meunier,Rudy Birsen,Lise Willems,Estelle Saland,Estelle Saland,Justine Decroocq,Thiago Trovati Maciel,Mireille Lambert,Laury Poulain,Pierre Sujobert,Laure Joseph,Nicolas Chapuis,Nicolas Chapuis,Catherine Lacombe,Catherine Lacombe,Ivan C. Moura,Susan Demo,Jean-Emmanuel Sarry,Jean-Emmanuel Sarry,Christian Recher,Christian Recher,Patrick Mayeux,Patrick Mayeux,Jerome Tamburini,Didier Bouscary +28 more
TL;DR: It is shown that glutamine levels control mitochondrial oxidative phosphorylation (OXPHOS) in acute myeloid leukemia (AML) cells and targeting glutamine addiction via GLS1 inhibition offers a potential novel therapeutic strategy for AML.
Journal ArticleDOI
Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia
Pierre Sujobert,Valérie Bardet,Pascale Cornillet-Lefebvre,Joel S. Hayflick,Nolwen Prie,Frederic Verdier,Bart Vanhaesebroeck,Odile Muller,Florence Pesce,Norbert Ifrah,Mathilde Hunault-Berger,Christian Berthou,Bruno Villemagne,Eric Jourdan,Bruno Audhuy,Eric Solary,Brigitte Witz,Jean Luc Harousseau,Chantal Himberlin,Thierry Lamy,Bruno Lioure,Jean-Yves Cahn,François Dreyfus,Patrick Mayeux,Catherine Lacombe,Didier Bouscary +25 more
TL;DR: It is shown that the p110δ isoform of PI3K is consistently expressed at a high level in blast cells from AML, in contrast to the other class I isoforms, the expression of which was very variable among patients.
Journal ArticleDOI
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Jerome Tamburini,Nicolas Chapuis,Valérie Bardet,Sophie Park,Pierre Sujobert,Lise Willems,Lise Willems,Lise Willems,Norbert Ifrah,François Dreyfus,Patrick Mayeux,Patrick Mayeux,Patrick Mayeux,Catherine Lacombe,Didier Bouscary +14 more
TL;DR: The results suggest that dual inhibition of the mTORC1 complex and the IGF-1/IGF-1R/PI3K/Akt pathway in AML may enhance the efficacy of mTOR inhibitors in treatment of this disease.